S5959 Two Sides of the Same Coin: Contrasting Presentations and Outcomes of Hepatitis E Virus Infection in a Transplant Recipient and an Immunocompetent Host

Introduction: Hepatitis E virus (HEV) is a non-enveloped RNA virus known to cause self-limited hepatitis in immunocompetent individuals but may lead to chronic infection in immunocompromised hosts. In rare cases, HEV can cause acute liver failure (ALF). We present 2 contrasting cases that illustrate the clinical spectrum of HEV infection and underscore the importance of early recognition and tailored management. Case Description/Methods: Case 1 shows acute liver failure in an immunocompetent host. A 67-year-old man with diabetes and coronary artery disease presented with jaundice and hepatic encephalopathy. Labs revealed aspartate aminotransferase (AST) 9,813 U/L, alanine aminotransferase (ALT) 7,057 U/L, bilirubin 16.8 mg/dL, international normalized ratio 3.5, and ammonia 109 µmol/L. HEV IgM, IgG, and RNA (4.56 million IU/mL) were positive. Liver biopsy showed severe hepatitis with bridging necrosis. Despite intensive care until-level care, he deteriorated rapidly and died 5 days later. Autopsy confirmed fulminant hepatic necrosis due to HEV. Case 2 demonstrates chronic HEV in a liver transplant recipient. A 47-year-old man with nonalcoholic steatohepatitis cirrhosis underwent liver transplantation. Three months later, he developed elevated liver enzymes (AST 133 U/L, ALT 573 U/L). Biopsies showed mild hepatitis without rejection. HEV RNA was positive (5.5 million IU/mL). He was treated with ribavirin 400 mg BID and adjustments in immunosuppression. After 12 weeks, liver enzymes normalized, and HEV RNA became undetectable. He remained well 3-months post-treatment. Discussion: These cases highlight the divergent outcomes of HEV based on host immune status. The immunocompetent patient developed fulminant hepatitis and died, despite having a similar viral load to the transplant recipient who recovered with antiviral therapy. In immunocompromised patients, HEV may present subtly but progress to chronicity. Early HEV testing should be considered in patients with unexplained hepatitis, particularly those with recent transplantation or systemic stress. Prompt diagnosis and appropriate therapy can significantly alter outcomes.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001151296.00747.d7
Primary Topic
Hepatitis Viruses Studies and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S5959 Two Sides of the Same Coin: Contrasting Presentations and Outcomes of Hepatitis E Virus Infection in a Transplant Recipient and an Immunocompetent Host

John Erikson Yap, Juan Fernando Gallegos-Orozco, Gillian Hale, Avneet Singh et al.
The American Journal of Gastroenterology
Hepatitis Viruses Studies and Epidemiology
article

S5959 Two Sides of the Same Coin: Contrasting Presentations and Outcomes of Hepatitis E Virus Infection in a Transplant Recipient and an Immunocompetent Host

John Erikson Yap, Juan Fernando Gallegos-Orozco, Gillian Hale, Avneet Singh, Mina Awadallah, Mariana Moreno-Prats
article en

Abstract

Introduction: Hepatitis E virus (HEV) is a non-enveloped RNA virus known to cause self-limited hepatitis in immunocompetent individuals but may lead to chronic infection in immunocompromised hosts. In rare cases, HEV can cause acute liver failure (ALF). We present 2 contrasting cases that illustrate the clinical spectrum of HEV infection and underscore the importance of early recognition and tailored management. Case Description/Methods: Case 1 shows acute liver failure in an immunocompetent host. A 67-year-old man with diabetes and coronary artery disease presented with jaundice and hepatic encephalopathy. Labs revealed aspartate aminotransferase (AST) 9,813 U/L, alanine aminotransferase (ALT) 7,057 U/L, bilirubin 16.8 mg/dL, international normalized ratio 3.5, and ammonia 109 µmol/L. HEV IgM, IgG, and RNA (4.56 million IU/mL) were positive. Liver biopsy showed severe hepatitis with bridging necrosis. Despite intensive care until-level care, he deteriorated rapidly and died 5 days later. Autopsy confirmed fulminant hepatic necrosis due to HEV. Case 2 demonstrates chronic HEV in a liver transplant recipient. A 47-year-old man with nonalcoholic steatohepatitis cirrhosis underwent liver transplantation. Three months later, he developed elevated liver enzymes (AST 133 U/L, ALT 573 U/L). Biopsies showed mild hepatitis without rejection. HEV RNA was positive (5.5 million IU/mL). He was treated with ribavirin 400 mg BID and adjustments in immunosuppression. After 12 weeks, liver enzymes normalized, and HEV RNA became undetectable. He remained well 3-months post-treatment. Discussion: These cases highlight the divergent outcomes of HEV based on host immune status. The immunocompetent patient developed fulminant hepatitis and died, despite having a similar viral load to the transplant recipient who recovered with antiviral therapy. In immunocompromised patients, HEV may present subtly but progress to chronicity. Early HEV testing should be considered in patients with unexplained hepatitis, particularly those with recent transplantation or systemic stress. Prompt diagnosis and appropriate therapy can significantly alter outcomes.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 47%
Hepatitis Viruses Studies and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.